Doctaverse

Henoch-Schönlein Purpura (IgA Vasculitis): A Clinician's Monograph

Concise clinician reference on HSP / IgA vasculitis — EULAR/PRINTO/PRES 2010 criteria, the tetrad of features, renal surveillance, and red flags.

Full criteria: Henoch-Schönlein Purpura.

Definition and epidemiology

Henoch-Schönlein purpura (HSP), now termed IgA vasculitis (IgAV), is the commonest systemic vasculitis of childhood — a small-vessel, immune-complex (IgA1-dominant) leukocytoclastic vasculitis. Annual incidence is roughly 10–20 per 100,000 children, with peak onset at 4–6 years and a slight male predominance. About 90% of cases occur in children, often 1–3 weeks after an upper respiratory infection (group A streptococcus among the implicated triggers), with autumn–winter clustering.

It is usually a self-limiting illness lasting 4–6 weeks, but up to a third relapse, and the kidney determines long-term prognosis.

Clinical features

The classic tetrad:

Scrotal involvement (orchitis) can mimic testicular torsion. Subcutaneous oedema of the scalp, hands and feet is common in younger children.

Diagnosis

HSP is a clinical diagnosis. The validated EULAR/PRINTO/PRES (Ankara 2008) classification criteria require purpura or petechiae with lower-limb predominance (mandatory) plus at least one of: diffuse abdominal pain, arthritis/arthralgia, renal involvement (haematuria/proteinuria), or a biopsy showing leukocytoclastic vasculitis or proliferative GN with predominant IgA deposition — sensitivity ~100%, specificity ~87%. Atypical distribution or features warrant skin/renal biopsy and exclusion of mimics (meningococcaemia, ITP, HUS, ANCA vasculitis, acute haemorrhagic oedema of infancy).

See the full criteria: Henoch-Schönlein Purpura (IgA Vasculitis)

Red flags

Management overview

Most children need only supportive care: rest, hydration, and analgesia. NSAIDs help arthralgia but are avoided with significant renal involvement or GI bleeding. Corticosteroids (oral prednisolone, or IV methylprednisolone in severe disease) are reserved for significant GI involvement (severe pain, bleeding), orchitis, or severe nephritis — they do not prevent nephritis and should not be used prophylactically. Significant or progressive HSP nephritis is managed with steroids ± immunosuppression (e.g. mycophenolate, cyclophosphamide) per SHARE recommendations, with pediatric nephrology referral.

The key to follow-up is renal surveillance: blood pressure and urinalysis at diagnosis and regularly for 6–12 months, even after the rash resolves, because nephritis can be delayed. Persistent proteinuria mandates nephrology referral.

References

  1. Ozen S, et al. EULAR/PRINTO/PRES Ankara 2008 criteria. Ann Rheum Dis. 2010;69:798–806.
  2. Ozen S, et al. SHARE recommendations for IgA vasculitis. Rheumatology. 2019;58:1607–1616.
  3. Nelson Textbook of Pediatrics, 21st ed.

Decision support for qualified clinicians only — verify against current primary guidelines and your clinical judgement.

References

Last updated 2026-06-28.

More like this

Dengue in Children: A Clinician's Monograph

Clinician reference on paediatric dengue — WHO 2009 classification, warning signs, NS1/serology, fluid management of the critical phase, and red flags.

Febrile Seizures: A Clinician's Monograph

Clinician reference on febrile seizures — simple vs complex definitions, AAP neurodiagnostic evaluation, when to do an LP, recurrence risk, and red flags.

Guillain-Barré Syndrome in Children: A Clinician's Monograph

Concise clinician reference on pediatric GBS — Brighton case definition, albuminocytologic dissociation, IVIG/plasma exchange, and respiratory red flags.

Kawasaki Disease: A Clinician's Monograph

Concise clinician reference on Kawasaki disease — AHA 2017 criteria for classic and incomplete KD, coronary risk, IVIG/aspirin therapy, and red flags.